Blocking the immunosuppressive axis with small interfering RNA targeting interleukin (IL)-10 receptor enhances dendritic cell-based vaccine potency

Clinical and Experimental Immunology

Volumn 165, Issue 2, 2011, Pages 180-189

  Kim, J H ^a   Kang, T H ^a   Noh, K H ^a   Bae, H C ^a   Ahn, Y H ^a   Lee, Y H ^a   Choi, E Y ^b   Chun, K H ^c   Lee, S J ^c   Kim, T W ^a  

^a Korea University College of Medicine   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c National Cancer Center   (South Korea)

Author keywords

Dendritic cell; IL 10 receptor; Immunosuppression; Immunotherapy; SiRNA

Indexed keywords

CD40 ANTIGEN; DENDRITIC CELL VACCINE; HLA ANTIGEN CLASS 2; INTERLEUKIN 10 RECEPTOR; INTERLEUKIN 12; LIPOPOLYSACCHARIDE; PROTEIN E7; RECOMBINANT INTERLEUKIN 10; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; DRUG POTENCY; FEMALE; FLOW CYTOMETRY; GENE TARGETING; MOUSE; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; TUMOR CELL; UPREGULATION;

ANIMALS; ANTIGENS, CD40; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; DOWN-REGULATION; FEMALE; FLOW CYTOMETRY; GENES, MHC CLASS II; IMMUNE TOLERANCE; INTERLEUKIN-10; INTERLEUKIN-12; LIPOPOLYSACCHARIDES; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; PAPILLOMAVIRUS E7 PROTEINS; RECEPTORS, INTERLEUKIN-10; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, SMALL INTERFERING; TH1 CELLS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 79960039023     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2011.04410.x     Document Type: Article

References (28)

1. Schuler G, Schuler-Thurner B, Steinman RM. The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 2003; 15:138-47.
2. Huang M, Sharma S, Mao JT, Dubinett SM. Non-small cell lung cancer-derived soluble mediators and prostaglandin E2 enhance peripheral blood lymphocyte IL-10 transcription and protein production. J Immunol 1996; 157:5512-20.
3. Huang M, Stolina M, Sharma S etal. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res 1998; 58:1208-16.
4. Sharma S, Stolina M, Lin Y etal. T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function. J Immunol 1999; 163:5020-8.
5. Seo N, Hayakawa S, Takigawa M, Tokura Y. Interleukin-10 expressed at early tumour sites induces subsequent generation of CD4(+) T-regulatory cells and systemic collapse of antitumour immunity. Immunology 2001; 103:449-57.
6. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19:683-765.
7. Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB. Interleukin-10 and related cytokines and receptors. Annu Rev Immunol 2004; 22:929-79.
8. Kim VN. Small RNAs: classification, biogenesis, and function. Mol Cells 2005; 19:1-15.
9. Pai SI, Lin YY, Macaes B, Meneshian A, Hung CF, Wu TC. Prospects of RNA interference therapy for cancer. Gene Ther 2006; 13:464-77.
10. Kim JH, Kang TH, Noh KH etal. Enhancement of dendritic cell-based vaccine potency by anti-apoptotic siRNAs targeting key pro-apoptotic proteins in cytotoxic CD8(+) T cell-mediated cell death. Immunol Lett 2009; 122:58-67.
11. Kim TW, Lee JH, He L etal. Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency. Cancer Res 2005; 65:309-16.
12. Kang TH, Lee JH, Noh KH etal. Enhancing dendritic cell vaccine potency by combining a BAK/BAX siRNA-mediated antiapoptotic strategy to prolong dendritic cell life with an intracellular strategy to target antigen to lysosomal compartments. Int J Cancer 2007; 120:1696-703.
13. Peng S, Kim TW, Lee JH etal. Vaccination with dendritic cells transfected with BAK and BAX siRNA enhances antigen-specific immune responses by prolonging dendritic cell life. Hum Gene Ther 2005; 16:584-93.
14. Kim JH, Kang TH, Noh KH etal. Enhancement of DC vaccine potency by activating the PI3K/AKT pathway with a small interfering RNA targeting PTEN. Immunol Lett 2010; 134:47-54.
15. Ji H, Wang TL, Chen CH etal. Enhancement of dendritic cell-based vaccine potency by targeting antigen to endosomal/lysosomal compartments. Immunol Lett 2006; 106:126-34.
16. Samarasinghe R, Tailor P, Tamura T, Kaisho T, Akira S, Ozato K. Induction of an anti-inflammatory cytokine, IL-10, in dendritic cells after toll-like receptor signaling. J Interferon Cytokine Res 2006; 26:893-900.
17. Zhou L, Nazarian AA, Smale ST. Interleukin-10 inhibits interleukin-12 p40 gene transcription by targeting a late event in the activation pathway. Mol Cell Biol 2004; 24:2385-96.
18. O'Garra A, Hosken N, Macatonia S, Wenner CA, Murphy K. The role of macrophage- and dendritic cell-derived IL12 in Th1 phenotype development. Res Immunol 1995; 146:466.
19. Corinti S, Albanesi C, la Sala A, Pastore S, Girolomoni G. Regulatory activity of autocrine IL-10 on dendritic cell functions. J Immunol 2001; 166:4312-18.
20. Enk AH, Angeloni VL, Udey MC, Katz SI. Inhibition of Langerhans cell antigen-presenting function by IL-10. A role for IL-10 in induction of tolerance. J Immunol 1993; 151:2390-8.
21. Bellinghausen I, Sudowe S, König B, Reske-Kunz AB, Knop J, Saloga J. Interleukin-10-treated dendritic cells do not inhibit Th2 immune responses in ovalbumin/alum-sensitized mice. Int Arch Allergy Immunol 2006; 141:61-9.
22. Enk AH, Saloga J, Becker D, Mohamadzadeh M, Knop J. Induction of hapten-specific tolerance by interleukin 10 in vivo. J Exp Med 1994; 179:1397-402.
23. Pawelec G. Tumour escape: antitumour effectors too much of a good thing? Cancer Immunol Immunother 2004; 53:262-74.
24. Haase C, Jorgensen TN, Michelsen BK. Both exogenous and endogenous interleukin-10 affects the maturation of bone-marrow-derived dendritic cells in vitro and strongly influences T-cell priming in vivo. Immunology 2002; 107:489-99.
25. Murray PJ. STAT3-mediated anti-inflammatory signalling. Biochem Soc Trans 2006; 34:1028-31.
26. Ding Y, Qin L, Zamarin D etal. Differential IL-10R1 expression plays a critical role in IL-10-mediated immune regulation. J Immunol 2001; 167:6884-92.
27. Mocellin S, Marincola FM, Young HA. Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol 2005; 78:1043-51.
28. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993; 75:263-74.